New Stock News | Jiangfeng Medical Plans Hong Kong IPO China Securities Regulatory Commission Requires Explanation of Reasons for Approval Not Being Able to List in Hong Kong

According to the WiseFinance APP, on December 19, the China Securities Regulatory Commission announced the supplementary material requirements for overseas issuance and listing approval disclosure (December 15, 2025 - December 19, 2025). The CSRC requires Jingfeng Medical to explain whether the company's application for listing in Hong Kong in July 2022 was approved by the Commission, but was not listed in Hong Kong within the validity period of the approval. This is to determine if it constitutes a substantial obstacle to the current listing in Hong Kong. According to the Hong Kong Stock Exchange disclosure on January 11, 2023, Jingfeng Medical has submitted an application to the Hong Kong Stock Exchange, with Morgan Stanley, CICC, and Citigroup serving as joint sponsors.